Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Children with type 1 Gaucher disease: Changing profiles in the 21st century.

Elstein D, Altarescu G, Abrahamov A, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:93-96. doi: 10.1016/j.bcmd.2016.12.009. Epub 2016 Dec 19.

PMID:
28185830
2.

Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center.

Mendelsohn E, Meir A, Abrahamov A, Elstein D, Zimran A, Levy-Khademi F.

Blood Cells Mol Dis. 2018 Feb;68:97-99. doi: 10.1016/j.bcmd.2016.11.014. Epub 2016 Dec 9.

PMID:
27993449
3.

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.

Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R.

Blood Cells Mol Dis. 2018 Feb;68:163-172. doi: 10.1016/j.bcmd.2016.10.005. Epub 2016 Oct 20.

4.

13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.

Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A.

Blood Cells Mol Dis. 2015 Dec;55(4):415-8. doi: 10.1016/j.bcmd.2015.09.002. Epub 2015 Sep 21. Review.

PMID:
26460268
5.

Omentum ECM-based hydrogel as a platform for cardiac cell delivery.

Shevach M, Zax R, Abrahamov A, Fleischer S, Shapira A, Dvir T.

Biomed Mater. 2015 May 13;10(3):034106. doi: 10.1088/1748-6041/10/3/034106.

PMID:
25970726
6.

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.

Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, Chertkoff R.

Blood Cells Mol Dis. 2015 Jan;54(1):9-16. doi: 10.1016/j.bcmd.2014.10.002. Epub 2014 Nov 7.

7.

Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience.

Tukan I, Hadas-Halpern I, Altarescu G, Abrahamov A, Elstein D, Zimran A.

Adv Hematol. 2013;2013:151506. doi: 10.1155/2013/151506. Epub 2013 Oct 28.

8.

Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.

Elstein D, Abrahamov A, Altarescu G, Zimran A.

Blood Cells Mol Dis. 2013 Feb;50(2):140. doi: 10.1016/j.bcmd.2012.09.008. Epub 2012 Oct 22. No abstract available.

PMID:
23085428
9.

Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.

Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.

Blood Cells Mol Dis. 2012 Jan 15;48(1):45-50. doi: 10.1016/j.bcmd.2011.09.009. Epub 2011 Nov 1.

PMID:
22047948
10.

Sixteen years of prenatal consultations for the N370S/N370S Gaucher disease genotype: what have we learned?

Eitan Y, Abrahamov A, Phillips M, Elstein D, Zimran A.

Prenat Diagn. 2010 Oct;30(10):924-7. doi: 10.1002/pd.2584.

PMID:
20721872
11.

Gaucher disease: spectrum of sonographic findings in the liver.

Hadas-Halpern I, Deeb M, Abrahamov A, Zimran A, Elstein D.

J Ultrasound Med. 2010 May;29(5):727-33.

PMID:
20427784
12.

Disease severity in sibling pairs with type 1 Gaucher disease.

Elstein D, Gellman A, Altarescu G, Abrahamov A, Hadas-Halpern I, Phillips M, Margalit M, Lebel E, Itzchaki M, Zimran A.

J Inherit Metab Dis. 2010 Feb;33(1):79-83. doi: 10.1007/s10545-009-9024-7. Epub 2010 Jan 5.

PMID:
20049528
13.

Gaucher disease in Arab patients at an Israeli referral clinic.

Brautbar A, Abrahamov A, Hadas-Halpern I, Elstein D, Zimran A.

Isr Med Assoc J. 2008 Aug-Sep;10(8-9):600-2.

14.

Objectives and methods of iron chelation therapy.

Hershko C, Abrahamov A, Konijn AM, Breuer W, Cabantchik IZ, Pootrakul P, Link G.

Bioinorg Chem Appl. 2003:151-68. doi: 10.1155/S1565363303000128.

15.

Outcome of ten years' echocardiographic follow-up in children with Gaucher disease.

Rosengarten D, Abrahamov A, Nir A, Farber B, Glaser J, Zimran A, Elstein D.

Eur J Pediatr. 2007 Jun;166(6):549-51. Epub 2006 Aug 29.

PMID:
16941127
16.

A comprehensive assessment of renal function in patients with Gaucher disease.

Becker-Cohen R, Elstein D, Abrahamov A, Algur N, Rudensky B, Hadas-Halpern I, Zimran A, Frishberg Y.

Am J Kidney Dis. 2005 Nov;46(5):837-44.

PMID:
16253723
17.

Uncomplicated outcome after anesthesia for pediatric patients with Gaucher disease.

Ioscovich A, Briskin A, Abrahamov A, Halpern S, Zimran A, Elstein D.

Can J Anaesth. 2005 Oct;52(8):845-7.

PMID:
16189337
18.

Survey of hematological aspects of Gaucher disease.

Zimran A, Altarescu G, Rudensky B, Abrahamov A, Elstein D.

Hematology. 2005 Apr;10(2):151-6. Review.

PMID:
16019462
19.

Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic.

Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D.

Blood Cells Mol Dis. 2005 May-Jun;34(3):197-200.

PMID:
15885601
20.

Phenotypic heterogeneity in patients with Gaucher disease and the N370S/V394L genotype.

Elstein D, Scott CR, Zeigler M, Abrahamov A, Zimran A.

Genet Test. 2005 Spring;9(1):26-9.

PMID:
15857183
21.

N-brain natriuretic peptide: correlation with tricuspid insufficiency in Gaucher disease.

Elstein D, Nir A, Klutstein M, Abrahamov A, Zimran A.

Pulm Pharmacol Ther. 2004;17(5):319-23.

PMID:
15477128
22.

Effect of enzyme replacement therapy on gammopathies in Gaucher disease.

Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A.

Blood Cells Mol Dis. 2004 Jan-Feb;32(1):214-7.

PMID:
14757437
23.

The 1604A (R496H) mutation in Gaucher disease: genotype/phenotype correlation.

Brautbar A, Elstein D, Abrahamov A, Zeigler M, Chicco G, Beutler E, Scott CR, Zimran A.

Blood Cells Mol Dis. 2003 Sep-Oct;31(2):187-9; discussion 190-1.

PMID:
12972024
24.

Plasma chitotriosidase activity in patients with beta-thalassemia.

Altarescu G, Rudensky B, Abrahamov A, Goldfarb A, Rund D, Zimran A, Elstein D.

Am J Hematol. 2002 Sep;71(1):7-10.

25.

Type I Gaucher disease in children with and without enzyme therapy.

Dweck A, Abrahamov A, Hadas-Halpern I, Bdolach-Avram T, Zimran A, Elstein D.

Pediatr Hematol Oncol. 2002 Sep;19(6):389-97.

PMID:
12186361
26.

Gaucher disease: pediatric concerns.

Elstein D, Abrahamov A, Dweck A, Hadas-Halpern I, Zimran A.

Paediatr Drugs. 2002;4(7):417-26. Review.

PMID:
12083970
27.
28.

Spectrum of abdominal sonographic findings in 103 pediatric patients with Gaucher disease.

Patlas M, Hadas-Halpern I, Abrahamov A, Elstein D, Zimran A.

Eur Radiol. 2002 Feb;12(2):397-400. Epub 2001 Sep 7.

PMID:
11870441
29.

Castleman disease in pregnancy.

Abramov Y, Nadjari M, Abrahamov A, Reinus C, Anteby SO.

Obstet Gynecol. 1997 Oct;90(4 Pt 2):653-4. Review.

PMID:
11770581
30.

High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population.

Gielchinsky Y, Elstein D, Green R, Miller JW, Elstein Y, Algur N, Lahad A, Shinar E, Abrahamov A, Zimran A.

Br J Haematol. 2001 Dec;115(3):707-9.

PMID:
11736958
31.

Ethical guidelines for enzyme therapy in neuronopathic Gaucher disease.

Elstein D, Steinberg A, Abrahamov A, Zimran A.

Am J Hum Genet. 1997 Oct;61(4):A354. No abstract available.

PMID:
11644969
32.

How B12 deficiency can impact on the individual and how society can impact on B12 deficiency.

Gielchinsky Y, Elstein D, Abrahamov A, Zimran A.

Isr Med Assoc J. 2001 Sep;3(9):672-4. No abstract available.

33.

Wandering spleen in a young girl with Gaucher disease.

Dweck A, Abrahamov A, Hadas-Halpern I, Zimran A, Elstein D.

Isr Med Assoc J. 2001 Aug;3(8):623-4. No abstract available.

34.

Gaucher's disease.

Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A.

Lancet. 2001 Jul 28;358(9278):324-7. No abstract available.

PMID:
11498237
35.

Lung involvement and enzyme replacement therapy in Gaucher's disease.

Goitein O, Elstein D, Abrahamov A, Hadas-Halpern I, Melzer E, Kerem E, Zimran A.

QJM. 2001 Aug;94(8):407-15.

PMID:
11493717
36.

Viral infections and phenotypic heterogeneity in Gaucher disease.

Pines G, Morag A, Elstein D, Abrahamov A, Zimran A.

Blood Cells Mol Dis. 2001 Mar-Apr;27(2):358-61.

PMID:
11259156
37.

A new exon 9 glucose-6-phosphate dehydrogenase mutation (G6PD "Rehovot") in a Jewish Ethiopian family with variable phenotypes.

Iancovici-Kidon M, Sthoeger D, Abrahamov A, Wolach B, Beutler E, Gelbart T, Barak Y.

Blood Cells Mol Dis. 2000 Dec;26(6):567-71. Erratum in: Blood Cells Mol Dis 2001 Jan-Feb;27(1):351. Volach B [corrected to Wolach B].

PMID:
11112389
38.

Withdrawal of enzyme replacement therapy in Gaucher's disease.

Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A.

Br J Haematol. 2000 Aug;110(2):488-92.

PMID:
10971413
39.

Type IIIc Gaucher disease and acrodysostosis.

Abrahamov A, Elstein D, Zimran A.

Isr Med Assoc J. 2000 Feb;2(2):182. No abstract available.

40.

Children with type I Gaucher disease: growing into adulthood with and without enzyme therapy.

Zimran A, Abrahamov A, Elstein D.

Isr Med Assoc J. 2000 Feb;2(2):80-1. No abstract available.

41.

Skeletal manifestations in Gaucher disease: presentation and treatment.

Lebel E, Itzchaki M, Elstein D, Hadas-Halpern I, Abrahamov A, Zimran A.

Isr Med Assoc J. 1999 Dec;1(4):267-71. Review. No abstract available.

PMID:
10731360
42.

Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease.

Gielchinsky Y, Elstein D, Hadas-Halpern I, Lahad A, Abrahamov A, Zimran A.

Br J Haematol. 1999 Sep;106(3):812-6.

PMID:
10468878
43.

Asymptomatic Gaucher disease implications for large-scale screening.

Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A.

Genet Test. 1998;2(4):297-9.

PMID:
10464607
44.

Cytokines in Gaucher's disease.

Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S.

Eur Cytokine Netw. 1999 Jun;10(2):205-10.

45.

Recommendations for diagnosis, evaluation, and monitoring of patients with Gaucher disease.

Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A.

Arch Intern Med. 1999 Jun 14;159(11):1254-5. No abstract available.

PMID:
10371236
46.

Platelet function abnormalities in Gaucher disease patients.

Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A.

Am J Hematol. 1999 Jun;61(2):103-6.

47.

Echocardiographic assessment of pulmonary hypertension in Gaucher's disease.

Elstein D, Klutstein MW, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A.

Lancet. 1998 May 23;351(9115):1544-6.

PMID:
10326537
48.

Effect of vitamin K1 on glucose-6-phosphate dehydrogenase deficient neonatal erythrocytes in vitro.

Kaplan M, Waisman D, Mazor D, Hammerman C, Bader D, Abrahamov A, Meyerstein N.

Arch Dis Child Fetal Neonatal Ed. 1998 Nov;79(3):F218-20.

49.

Gaucher's disease with valve calcification: possible role of Gaucher cells, bone matrix proteins and integrins.

Veinot JP, Elstein D, Hanania D, Abrahamov A, Srivatsa S, Zimran A.

Can J Cardiol. 1999 Feb;15(2):211-6.

PMID:
10079781
50.

Favism by proxy in nursing glucose-6-phosphate dehydrogenase-deficient neonates.

Kaplan M, Vreman HJ, Hammerman C, Schimmel MS, Abrahamov A, Stevenson DK.

J Perinatol. 1998 Nov-Dec;18(6 Pt 1):477-9.

PMID:
9848766

Supplemental Content

Loading ...
Support Center